Citations

Clear

6055 citation(s) found for "Vu, Peter".

Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast
Huang, Huaizhi , Couch, Ronan E. , Karam, Rachid , Boddicker, Nicholas , Polley, Eric C. , Na, Jie , Ambrosone, Christine B. , Yao, Song , Trentham‐Dietz, Amy , Bodelón, Clara , Hodge, James M. , Patel, Alpa V. , Haiman, Christopher A. , John, Esther M. , Vachon, Celine M. , Ruddy, Kathryn J. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Dolinsky, Jill S. , Pesaran, Tina , Hu, Chunling , Boddicker, Nicholas J , Polley, Eric C , Na, Jie , Ambrosone, Christine B , Yao, Song , Trentham-Dietz, Amy , Eliassen, A Heather , Penney, Kathryn , Brantley, Kristen D , Bodelon, Clara , Teras, Lauren R , Hodge, James M , Patel, Alpa V , Haiman, Christopher A , John, Esther M , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Lacey, James V. , O'Brien, Katie M , Sandler, Dale P , Weinberg, Clarice R , Palmer, Julie R , Bertrand, Kimberly A , Vachon, Celine M. , Olson, Janet E , Ruddy, Kathryn J , Anton-Culver, Hoda , Ziogas, Argyrios , Goldgar, David E , Nathanson, Katherine L , Domchek, Susan M , Weitzel, Jeffrey N , Kraft, Peter , Dolinsky, Jill S , Pesaran, Tina , Richardson, Marcy E , Yadav, Siddhartha , Couch, Fergus J. , Karam, Rachid , Huang, Huaizhi , Couch, Ronan , Hu, Chunling , Eliassen, A. Heather , Brantley, Kristen D. , Teras, Lauren R. , O’Brien, Katie M. , Sandler, Dale P. , Weinberg, Clarice R. , Palmer, Julie R. , Bertrand, Kimberly A. , Olson, Janet E. , Anton‐Culver, Hoda , Ziogas, Argyrios , Domchek, Susan M. , Kraft, Peter , Yadav, Siddhartha , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | November 8, 2024 | Volume: 31 | Issue: 1 | Pages: 130-138

10.1158/1078-0432.ccr-24-1884 | PMID 39513960 Get It

Abstract Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Prognosis of patients with wild‐type transthyretin cardiac amyloidosis and non‐sustained ventricular tachycardia
Sehrawat, Ojasav , Swain, William H., Alcantara, Hannah P., Tan, Nicholas Y. , Ezzeddine, Omar F. Abou, Grogan, Martha, Lin, Grace , Noseworthy, Peter A. , Siontis, Konstantinos C. , AbouEzzeddine, Omar F. , Abou Ezzeddine, Omar F, Noseworthy, Peter A , Siontis, Konstantinos C , AbouEzzeddine, Omar F , Grogan, Martha , Dispenzieri, Angela

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 7, 2024 | Volume: 36 | Issue: 1 | Pages: 124-134

10.1111/jce.16470 | PMID 39506467 Get It

AbstractIntroductionLittle is known regarding the prevalence and prognostic implications of non‐sustained ventricular tachycardia (NSVT) in patients with wild‐type transthyretin cardiac amyloidosis (ATTRwt‐CA). We aimed to investigate the prevalence of NSVT in patients with ATTRwr‐CA, and the association of NSVT with sustained ventricular arrhythmias (VA) and all‐cause mortality.MethodsIn a cohort of ATTRwt‐CA patients from 2011 to 2022 without prior sustained VA, we ascertained the presence and characteristics of NSVT during clinically indicated ambulatory Holter monitoring. Patients were stratified based on the presence of NSVT at baseline. The primary and secondary endpoints of sustained VA and all‐cause mortality, respectively, were assessed during follow‐up.ResultsThe cohort included 217 patients with ATTRwt‐CA (95% males, median age 75 years; median NYHA class 2). Baseline Holter monitoring demonstrated NSVT in 116 (53%) patients. During a median follow‐up of 27 months (IQR 16–45) after the index Holter monitor, 11 (5.1%) patients reached the primary endpoint of sustained VA (incidence 1.8 per 100 person‐years, all monomorphic VT), and 46 (21%) patients died. In univariable Cox proportional hazard model, NYHA class 3 or 4 heart failure (p = .048), the presence of NSVT (p = .04), the duration of longest NSVT run (p = .029), and the percentage of ventricular ectopy (p < .001) were associated with the primary outcome. When adjusting for age and NYHA class 3 or 4 heart failure, the presence of NSVT remained associated with the primary outcome (p = .03). All‐cause mortality was not significantly different between patients with and without NSVT. A cutoff for ventricular ectopy burden of 0.5%, the median for all patients in this study, was associated with increased risk in sustained VA (log‐rank p = .004) and mortality (log‐rank p = .02).ConclusionNSVT is highly prevalent among ATTRwt‐CA patients undergoing clinically indicated Holter monitoring and may confer an increased risk of incident sustained VA.
Surgical Predictors of Clinical Outcome 6 Years After Revision ACL Reconstruction
Group, The MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., York, James J. , Group, The MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 6, 2024 | Volume: 52 | Issue: 13 | Pages: 3286-3294

10.1177/03635465241288227 | PMID 39503722 Get It

Background: Revision anterior cruciate ligament (ACL) reconstruction has been documented to have inferior outcomes compared with primary ACL reconstruction. The reasons why remain unknown. Purpose: To determine whether surgical factors performed at the time of revision ACL reconstruction can influence a patient’s outcome at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who underwent revision ACL reconstruction were identified and prospectively enrolled between 2006 and 2011. Data collected included baseline patient characteristics, surgical technique and pathology, and a series of validated patient-reported outcome instruments: Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) subjective form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Marx activity rating score. Patients were followed up for 6 years and asked to complete the identical set of outcome instruments. Regression analysis was used to control for baseline patient characteristics and surgical variables to assess the surgical risk factors for clinical outcomes 6 years after surgery. Results: A total of 1234 patients were enrolled (716 men, 58%; median age, 26 years), and 6-year follow-up was obtained on 79% of patients (980/1234). Using an interference screw for femoral fixation compared with a cross-pin resulted in significantly better outcomes in 6-year IKDC scores (odds ratio [OR], 2.2; 95% CI, 1.2-3.9; P = .008) and KOOS sports/recreation and quality of life subscale scores (OR range, 2.2-2.7; 95% CI, 1.2-4.8; P < .01). Use of an interference screw compared with a cross-pin resulted in a 2.6 times less likely chance of having a subsequent surgery within 6 years. Use of an interference screw for tibial fixation compared with any combination of tibial fixation techniques resulted in significantly improved scores for IKDC (OR, 1.96; 95% CI, 1.3-2.9; P = .001); KOOS pain, activities of daily living, and sports/recreation subscales (OR range, 1.5-1.6; 95% CI, 1.0-2.4; P < .05); and WOMAC pain and activities of daily living subscales (OR range, 1.5-1.8; 95% CI, 1.0-2.7; P < .05). Use of a transtibial surgical approach compared with an anteromedial portal approach resulted in significantly improved KOOS pain and quality of life subscale scores at 6 years (OR, 1.5; 95% CI, 1.02-2.2; P≤ .04). Conclusion: There are surgical variables at the time of ACL revision that can modify clinical outcomes at 6 years. Opting for a transtibial surgical approach and choosing an interference screw for femoral and tibial fixation improved patients’ odds of having a significantly better 6-year clinical outcome in this cohort.
Safe Options for the Treatment of Mothers and Babies with Pregestational Diabetes
Benhalima, Katrien , Mathieu, Chantal , Napoli, Angela , Kudva, Yogish C. , Cypryk, Katarzyna , Hammond, Peter , Divakar, Hema , Hod, Moshe, Mathieu, Chantal , Cukierman‐Yaffe, Tali , Cyganek, Katarzyna

Mayo Clinic

Diabetes Technology & Therapeutics | November 6, 2024 | Volume: 27 | Issue: 2 | Pages: 91-92

10.1089/dia.2024.0499 | PMID 39501847 Get It

Impact of Dermoscopy Training on Diagnostic Accuracy, and Its Association With Biopsy and Referral Patterns Among Primary Care Providers: A Retrospective and Prospective Educational Intervention Study
Middleton, Hayden T. , Swanson, David C. , Sartori‐Valinotti, Julio C. , O’Laughlin, Danielle , Young, Peter A. , Merry, Stephen , Weatherly, Renee M., Boswell, Christopher L. , Swanson, David L, O'Laughlin, Danielle J , Merry, Stephen P , Fischer, Karen, Boswell, Christopher , Nelson, Kelly C. , Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | November 5, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241296625 | PMID 39498620 Get It

Background: Proper diagnosis in primary care is crucial due to the large number of skin cancer diagnoses each year and its associated growing economic burden. Understanding how primary care providers can be best trained in dermoscopy is instrumental in helping primary care providers differentiate benign and malignant cutaneous lesions so that appropriate action can be taken (eg, biopsy/referral to dermatology or reassurance). Objective: To assess the success of concise dermoscopy training among primary care providers. Design: A cohort study was conducted in primary care at Mayo Clinic, Rochester, including primary care physicians, nurse practitioners, and physician assistants in internal medicine and family medicine. Diagnostic accuracy was measured on standardized testing through image-based recognition and in clinical practice through observation of referral and biopsy patterns both before and after dermoscopy education, focused on the TADA plus method. Results: Forty-three primary care providers completed the image-based recognition tests, with significant improvement in mean score measured after dermoscopy training workshop (20%). Among the thirteen primary care providers who continued to use dermoscopy in clinical practice, a significant improvement (31%) in mean clinical diagnostic accuracy was observed comparing 1 year of practice data before versus after dermoscopy training. Conclusion: Improvement in diagnostic accuracy with utilization of the TADA plus method translates into clinical practice. Therefore, training primary care providers in dermoscopy may improve the dermatologic care patients receive in primary care, especially in rural or medically underserved areas where access to dermatology is limited.
Blood-Based Nanoparticle-Enhanced Quaking-Induced Conversion (Nano-QuIC): Inhibitor-Resistant Detection of Seeding Activity in Patients Diagnosed with Parkinson’s Disease
Christenson, Peter R. , Li, Manci , Ahn, Hyerim , Schmeichel, Ann M., Misra, Pinaki , Savica, Rodolfo , Low, Phillip A. , Singer, Wolfgang , Oh, Sang‐Hyun , Li, Danni , Ahn, Hyerim , Misra, Pinaki , Singer, Wolfgang , Park, Hye Yoon , Oh, Sang-Hyun , Jeong, Hyeonjeong, Li, Danni , Larsen, Peter A.

Mayo Clinic

Nano Letters | November 1, 2024 | Volume: 24 | Issue: 47 | Pages: 15016-15024

10.1021/acs.nanolett.4c03768 | PMID 39485864 Get It

Whys and Wherefores of Coronary Arterial Positive Remodeling
Onnis, Carlotta , Virmani, Renu , Madra, Anna , Nardi, Valentina , Montisci, Roberta , Cau, Riccardo , Boi, Alberto , Lerman, Amir , Cecco, Carlo N. De , Saba, Luca , Montisci, Roberta , Cau, Riccardo , Boi, Alberto , Lerman, Amir , De Cecco, Carlo N , Libby, Peter , Saba, Luca , Virmani, Renu , Nardi, Valentina , Salgado, Rodrigo , Libby, Peter

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | October 31, 2024 | Volume: 44 | Issue: 12 | Pages: 2416-2427

10.1161/atvbaha.124.321504 | PMID 39479766 Get It

Positive remodeling (PR) is an atherosclerotic plaque feature defined as an increase in arterial caliber at the level of an atheroma, in response to increasing plaque burden. The mechanisms that lead to its formation are incompletely understood, but its role in coronary atherosclerosis has major clinical implications. Indeed, plaques with PR have elevated risk of provoking acute cardiac events. Hence, PR figures among the high-risk plaque features that cardiac imaging studies should report. This review aims to provide an overview of the current literature on coronary PR. It outlines the pathophysiology of PR, the different techniques used to assess its presence, and the imaging findings associated to PR, on both noninvasive and invasive studies. This review also summarizes clinical observations, trials, and studies, focused on the impact of PR on clinical outcome.
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
Ahn, Daniel H. , Ridinger, Maya , Cannon, Timothy Lewis , Mendelsohn, Lawrence, Starr, Jason S. , Hubbard, Joleen M. , Kasi, Anup , Barzi, Afsaneh , Samuëlsz, Errin , Karki, Anju , Subramanian, Ramanand A. , Yemane, Divora, Kim, Roy , Wu, Chu-Chiao , Croucher, Peter J.P. , Smeal, Tod , Kabbinavar, Fairooz F. , Lenz, Heinz‐Josef , Cannon, Timothy L , Hubbard, Joleen

Mayo Clinic

Journal of Clinical Oncology | October 30, 2024 | Volume: 43 | Issue: 7 | Pages: 840-851

10.1200/jco-24-01266 | PMID 39475591 Get It

PURPOSE This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the second-line treatment of KRAS -mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS This multicenter, open-label, single-arm study enrolled patients with KRAS -mutated mCRC previously treated with oxaliplatin and fluorouracil with or without bevacizumab. Patients received onvansertib (15 mg/m 2 once daily on days 1-5 and 15-19 of a 28-day cycle) and FOLFIRI + bevacizumab (days 1 and 15). The primary end point was the objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), duration of response (DOR), and tolerability. Translational and preclinical studies were conducted in KRAS -mutant CRC. RESULTS Among the 53 patients treated, the confirmed ORR was 26.4% (95% CI, 15.3 to 40.3). The median DOR was 11.7 months (95% CI, 9.4 to not reached). Grade 3/4 adverse events were reported in 62% of patients. A post hoc analysis revealed that patients with no prior bevacizumab treatment had a significantly higher ORR and longer PFS compared with patients with prior bevacizumab treatment: ORR of 76.9% versus 10.0% (odds ratio of 30.0, P < .001) and median PFS of 14.9 months versus 6.6 months (hazard ratio of 0.16, P < .001). Our translational findings support that prior bevacizumab exposure contributes to onvansertib resistance. Preclinically, we showed that onvansertib inhibited the hypoxia pathway and exhibited robust antitumor activity in combination with bevacizumab through the inhibition of angiogenesis. CONCLUSION Onvansertib in combination with FOLFIRI + bevacizumab showed significant activity in the second-line treatment of patients with KRAS -mutant mCRC, particularly in patients with no prior bevacizumab treatment. These findings led to the evaluation of the combination in the first-line setting (ClinicalTrails.gov identifier: NCT06106308 ).
World delirium awareness and quality survey in 2023—a worldwide point prevalence study
Liu, Keibun , Szalacha, Laura A. , Ashkenazy, Shelly , Bellelli, Giuseppe , Gurjar, Mohan , Heras-La-Calle, Gabriel, Hoffman, Magdalena, Jeitziner, Marie‐Madlen , Krewulak, Karla D. , Paulino, Maria Carolina , Haken, Rebecca von , Nydahl, Peter , Team, For the WDAD Study, Blackwood, Bronagh , Calle, Gabriel Heras La , Hoffmann, Magdalena , Aggar, Christina , Bail, Kasia , Cacciatore, Stefano , Costello, Maria , Coimbra, Isabel , Olotu, Cynthia , Timmons, Suzanne , Ward‐Stockham, Kristel , Szalacha, Laura, Gurjar, Mohan , Nydahl, Peter , Jeitziner, Marie-Madlen , Krewulak, Karla D , Lindroth, Heidi , Boogaard, Mark van den , Caplan, Gideon A. , Chung, Chi Ryang , Elhadi, Muhammed , Hoffman, Magdalena, Mailhot, Tanya , Morandi, Alessandro , Nawa, Ricardo Kenji , Oh, Esther S , Collet, Marie Oxenbøll , Team, For the WDAD Study, Salis, Francesco

Mayo Clinic

Age and Ageing | October 30, 2024 | Volume: 53 | Issue: 11 | Pages: No page available

10.1093/ageing/afae248 | PMID 39568389 Get It

Abstract Background Delirium, an acute brain dysfunction, is proposed to be highly prevalent in clinical care and shown to significantly increase the risk of mortality and dementia. Objectives To report on the global prevalence of clinically documented delirium and delirium-related clinical practices in wards caring for paediatric and adult patients in healthcare facilities. Design A prospective, cross-sectional, 39-question survey completed on World Delirium Awareness Day, 15 March 2023. Participants Clinicians or researchers with access to clinical data. Main Outcome and Measure The primary outcome was the prevalence of clinically documented delirium at 8:00 a.m. (4 h) and 8:00 p.m. (±4 h). Secondary outcomes included delirium-related care practices and barriers to use. Descriptive statistics were calculated and multilevel modelling was completed. Results 1664 wards submitted surveys from 44 countries, reporting on delirium assessments at 8:00 a.m. (n = 36 048) and 8:00 p.m. (n = 32 867); 61% reported use of validated delirium assessment tools. At 8:00 a.m., 18% (n = 2788/15 458) and at 8:00 p.m., 17.7% (n = 2454/13 860) were delirium positive. Top prevention measures were pain management (86.7%), mobilisation (81.4%) and adequate fluids (80.4%). Frequently reported pharmacologic interventions were benzodiazepines (52.7%) and haloperidol (46.2%). Top barriers included the shortage of staff (54.3%), lack of time to educate staff (48.6%) and missing knowledge about delirium (38%). Conclusion and Relevance In this study, approximately one out of five patients were reported as delirious. The reported high use of benzodiazepines needs further evaluation as it is not aligned with best-practice recommendations. Findings provide a benchmark for future quality improvement projects and research.